Author: Patrick Seymour
Most employee health strategies have been built around supporting people once something has already gone wrong. In practice, that means support often starts late, with benefits like Private Medical Insurance (PMI) or Group Income Protection (GIP) stepping in to fund treatments, provide financial protection and support recovery. The value of these interventions shouldn't be understated and benefits like this remain essential parts of many wellbeing strategies.
However, the conversation is shifting. The adage of "prevention is better than cure" is unarguable and more employers are beginning to think about what earlier intervention might look like, particularly for high-impact conditions like cancer. This is already reflected in wider benefits strategy, with almost half (49.1%) of UK organisations now offering some form of health screening.
Screening is increasingly part of that discussion — not as a replacement for core benefits, but as a way of extending employee support, reducing risk and shifting benefits spend from cure to prevention.
Why the conversation is shifting
Poor workforce health carries a significant cost to UK employers through absence and lost productivity across all conditions.
The scale of cancer in the UK is hard to ignore. Over 400,000 people are diagnosed each year — roughly one person every couple of minutes. A proportion of cases are among the working-age population, with rising incidences in the 25-50 age group.
For employers, the impact is rarely limited to PMI and GIP claims costs alone. It's often felt through:
- Extended periods of absence
- Disruption across teams
- Increased management involvement
- In some cases, more gradual return-to-work arrangements
Absence in these cases is often measured in months rather than weeks. Employees may be off work for several months across diagnosis, treatment and recovery.
Even where insurance works exactly as expected that wider operational impact doesn't go away.
Understanding the cost of timing
Cancer is an area where timing can make a significant difference. Later diagnosis is generally associated with more intensive treatment, longer recovery and worse outcomes.
From an employer perspective, this often leads to longer and less predictable periods of absence, more complex treatment and a more gradual and phased return to work. This adds pressure on teams, driving higher absence and claims costs and making managing workloads more difficult due to the uncertainty of recovery timelines.
That translates directly into business disruption — both operationally and financially.
Increasingly, employers are recognising that earlier diagnosis can help reduce absence and long-term claims, shifting focus towards prevention rather than treatment alone.
This is where we could start to look at screening differently — less as an optional add-on with additional cost and more as part of a long term and strategic approach to managing health related risk and containing claims costs.
What screening can — and can't — do
Cancer screening isn't a complete solution, and expectations do need to be realistic.
It will not prevent cancer occurring and it doesn't remove the need for treatment or insurance-based benefits. What it can change is how early potential issues are picked up
There are a variety of cancer screening propositions on the market now and providers vary in approach and increasingly are moving away from a one-size-fits-all approach. While some still simply offer a screening service to those who choose to take it, others will use an assessment based on lifestyle and family history to target those most at risk of specific cancers and recommend specific screenings to them.
In our view, this data-led risk assessments approach, based on lifestyle and medical history, offers a more tangible benefit, as well as saving costs compared to a blanket screening approach.
Typically, the providers offering more targeted approaches also incorporate lifestyle advice on how to reduce risk. With four in ten cases of cancer preventable, education is a valuable part of an overall wellbeing strategy.
A market that has changed
Historically, screening was often offered as a one-off test, with limited support beyond the result. We've seen this shift over time with both clinical developments and a growing awareness of the value of preventative health.
Screening providers now offer a mix of at-home and clinic-based screening, covering multiple cancer types and supported by follow-up pathways. PMI Insurers have also adapted, with self-referral pathways resulting in faster access into diagnostics and onward care where required.
The distinction is important. The value of screening is no longer just in the test itself, but in what happens next - and how quickly that follow-up takes place.
This is where the pathway becomes critical. A positive result has limited value unless it leads quickly into diagnostics and, where needed, treatment.
In practice, that comes down to how screening links into insurer pathways or specialist providers, so employees can move from an initial flag through to diagnosis without delay. With providers still not fully joined up, this is where an engaging and comprehensive benefits communication approach is key, in order that employees know where to go next and how to find what they need.
Where implementation matters most
The effectiveness of any benefits programme depends heavily on how it's implemented and promoted and screening is no different.
Employers need to consider:
- Who the benefit's intended for
- Which cancers are covered
- How employees access the service
- How often screening is offered
- What happens if results are flagged
That final point is probably the most important. Screening is only the first stage — it needs to be followed by appropriate diagnostic testing and support where concerns are identified. Without a clear pathway, there is a risk of creating uncertainty rather than reassurance.
There is also a wider question for employers around whether cancer is a material issue within their population. Looking at claims data across PMI, GIP and GLA can help build that picture.
Where there is a clear impact, targeted screening and early intervention can form part of a more considered response, rather than being introduced in isolation.
Positioning within a wider strategy
Screening is most effective when it sits alongside existing benefits, rather than operating in isolation.
- PMI remains central to diagnosis and treatment
- Mental health support can help employees manage uncertainty or waiting periods
- Preventative programmes address underlying risk factors
In this sense, screening extends the existing approach. It doesn't replace treatment-based benefits but brings the starting point forward.
A gradual shift in focus
Not every employer will take the same view. Cost, workforce profile, claims data and existing provision will all (and should) influence decision making.
However, the direction of travel is becoming clearer. More organisations are considering how earlier intervention can sit alongside traditional healthcare benefits, particularly for high-impact conditions such as cancer.
For many, the question is no longer simply whether screening has a role, but how it fits within a balanced and practical health strategy.
A model that focuses on supporting employees once they are unwell still has clear value. But it also carries a level of cost — both human and financial — that is prompting a closer look at what earlier support could actually achieve in practice.
